CAI President Spetzler bought 400 shares at $23.85 on 2025-11-07; stock down 18.6% in 30 days, 23.6% in 90 days.
David Baxley Spetzler, President of Caris Life Sciences, purchased 400 shares for $9,540.00 at $23.85 on 2025-11-07, a modest addition to his 460.4K-share baseline position. The current price of $24.80 shows the stock has recovered slightly from the transaction price, but broader momentum is negative: the stock is down 18.6% over the past 30 days and down 23.6% over the past 90 days, trading 36.9% below its 52-week high of $39.30. The company maintains positive fundamentals with $24.3M in net income against $216.8M in quarterly revenue. This small-scale purchase in a weak price environment, combined with the insider's substantial pre-existing stake of 460.4K shares, provides a limited signal without additional context on the executive's broader trading pattern or board-wide activity.